MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST001660/mwtabprimaryOK200Mass SpectrometryESIMalariahttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST001660Treatment:No treatmentTreatment:Pooled Parasite SamplesTreatment:BlankTreatment:MMV019721Treatment:MMV084978Cultured CellsReversed phase NEGATIVE ION MODE.MetabolomicsWorkbenchMetabolomicsPlasmodium FalciparumPennsylvania State UniversityUDP-D-GlucoseHydroxyisocaproic acid2_3-Diphosphoglyceric acidGTPHexose3-PhosphoglycerateLactatedCDP4-AminobutyrateL-arginino-succinateCitrate/Isocitrate6-Phospho-D-GluconateisoleucineOrotateCDPUTPS-Adenosyl-L-HomocysteineGDParginineUDP-N-Acetyl-GlucosamineaspartateKetoleucineglutamateAcetyllysine4-phosphopantetheineorotidine-5'-phosphateSedoheptulose BisphosphateUDPleucineglucono-lactonebiotinCMP1_3-Bisphosphoglyceric aciddGTP/ATPGMPcoenzyme ACDP-EthanolaminefolateMalatemethioninedCTPdATPUMP5-phosphoribosyl-1-pyrophosphateN-Carbamoyl-L-AspartatedTMPNADPHdTTPCDP-cholineN-Acetyl-GlutamateglutathioneIndoleacetyl-aspartateasparagineCyclic-AMPglutamineSDdTDPNADHS-methyl-5'-thioadenosinePyroglutamic acidADP-D-Glucosehydroxyproline/AminolevulinateDihydroorotatePhenol Red5-aminopentanoic acid4-PhosphopantothenateMyo-InositolN-Acetyl-L-AlanineNADP+FMNNicotinateN-Acetyl-L-OrnithineFADdGMP/AMPAcetyl-CoAdCMPa-ketoglutaratemaleic aciddAMPGlucose-1/6-PhosphateFructose-1,6-BisphosphatechlorpropamideFumarateOctulose 8/1-PhosphatePDPEdGDP/ADPnicotinamide mononucleotideAconitateUDP-D-GlucuronatehistidineCTPNAD+PEEKGlutathione Disulfidetreatment, Therapy, Acetyl-CoA synthetase, 6.2.1.1, Therapeutic, Plasmodium (Laverania) falciparum, falciparums, disease management, Therapies, Plasmodium, ACS, AceCS, Acyl-activating enzyme., Metabonomic, Acetate--CoA ligase, Treatment, Metabonomics, malaria parasite P. falciparum, Metabolomic, Acyl-CoA synthetase short-chain family member 2, Plasmodium falciparums, Treatmentsbackward, reversed.falsePlasmodium falciparum metabolomics as a result of treatment with putative acetyl-CoA synthetase inhibitorsST0016605833